Pharmacophore-based virtual screening and in silico investigations of small molecule library for discovery of human hepatic ketohexokinase inhibitors for the treatment of fructose metabolic disorders
These findings highlight compound <b>2</b> as a potent KHK-C inhibitor with predicted pharmacokinetics and toxicity profiles supporting its potential for treating fructose-driven metabolic disorders, warranting further validation.
Authors
- Afnan Alsultan (ORCID: https://orcid.org/0000-0002-3857-1429)
- Musaed Rayzah (ORCID: https://orcid.org/0000-0003-2837-6141)
- Fares Rayzah
- Tilal Elsaman (ORCID: https://orcid.org/0000-0003-3875-7968)
- Nasser A. N. Alzerwi (ORCID: https://orcid.org/0000-0002-4877-2152)
- Jeremy Mills (ORCID: https://orcid.org/0000-0003-1719-9047)
- Heba Bassiony Ghanem (ORCID: https://orcid.org/0000-0002-7987-5111)
- Bandar Idrees
- Badr Alzahrani (ORCID: https://orcid.org/0000-0003-4158-640X)
- Abozer Y. Elderdery (ORCID: https://orcid.org/0000-0002-6219-5312)
- Magdi Awadalla Mohamed
- Abdullah Alsrhani (ORCID: https://orcid.org/0000-0002-6839-8866)
Institutions
- Riyadh Armed Forces Hospital (SA)
- Majmaah University (SA)
- Jouf University (SA)
- King Saud Medical City (SA)
- Portsmouth College (GB)
- Asir Central Hospital (SA)
- University of Portsmouth (GB)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3389/fphar.2025.1531512
- Citations
- 3
- Primary Topic
- Diet, Metabolism, and Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.88